Literature DB >> 10986065

Survival gain in cost-effectiveness studies.

S Trippoli, M Vaiani, A Messori, E Tendi.   

Abstract

Mesh：

Year:  2000        PMID： 10986065     DOI： 10.1200/JCO.2000.18.18.3318

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

Review 1.  Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.

Authors:  John A Carter; Avani D Joshi; Satyin Kaura; Marc F Botteman
Journal:  Pharmacoeconomics       Date:  2012-05       Impact factor: 4.981

2.  Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.

Authors:  M F Botteman; M Meijboom; I Foley; J M Stephens; Y M Chen; S Kaura
Journal:  Eur J Health Econ       Date:  2010-08-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.